Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories

10285,967

15/952504

April 13, 2018

In an embodiment, compositions comprising monoacylglycerols (MAG), such as sn-1 MAG, are administered with a lipase inhibitor, such as tetrahydrolipstatin, and/or with a diet low in fat and/or calories. In another embodiment, compositions comprising MAG, such as sn-1 MAG, are administered concurrently with a lipase inhibitor, such as tetrahydrolipstatin, and/or with fat-soluble nutrients. The compositions and the methods of using the compositions enhance absorption of fatty acids and fat-soluble nutrients such as fat-soluble vitamins and carotenoids to address nutritional deficiencies due to a weight loss diet used in association with a lipase inhibitor.

NESTEC S.A. (Vevey, CH)

Nestec S.A. (Vevey, CH)

1. A method of improving absorption of fat-soluble nutrients in an individual having a condition in which the absorption has been compromised, the condition is a low calorie diet in which 800 calories/day or less is consumed by the individual, the method comprising administering a fat-soluble nutrient and a therapeutically effective amount of monoacylglycerols to the individual.

2. The method of claim 1 wherein the monoacylglycerols are administered concurrently with the fat-soluble nutrient.

3. The method of claim 1 wherein the monoacylglycerols comprise a therapeutically effective amount of sn-1(3) monoacylglycerols.

4. The method of claim 1 wherein the amount of monoacylglycerols administered to the individual is therapeutically effective to enhance delivery of the fat-soluble nutrient in the individual.

5. The method of claim 1 wherein the monoacylglycerols comprise a functional fatty acid.

6. The method of claim 1 wherein the monoacylglycerols are selected from the group consisting of MAG-DHA, MAG-EPA and MAG-ARA.

7. The method of claim 1 comprising administering the fat-soluble nutrient and the monoacylglycerols to the individual daily for at least three weeks.

8. The method of claim 1 wherein the fat-soluble nutrient is selected from the group consisting of fat-soluble vitamins, carotenoids, and mixtures thereof.

9. The method of claim 1 wherein the fat-soluble nutrient is selected from the group consisting of vitamin A, isoforms of vitamin A, vitamin D, isoforms of vitamin D, vitamin E, isoforms of vitamin E, vitamin K, isoforms of vitamin K, beta-carotene, lutein, and mixtures thereof.

10. The method of claim 1 further comprising administering a lipase B inhibitor to the individual concurrently with the monoacylglycerols.

11. The method of claim 1 wherein no more than 25 wt. % of the monoacylglycerols are Sn-2 monoacylglycerols.

12. The method of claim 1 wherein no more than 15 wt. % of the monoacylglycerols are Sn-2 monoacylglycerols.

13. The method of claim 1 wherein the monoacylglycerols and the fat-soluble nutrient are administered in a composition in which the monoacylglycerols contribute 5% to 40% of the calorie content of the composition.

14. A method of improving absorption of fat-soluble nutrients in an individual having a having a condition in which the absorption has been compromised, the condition is a low fat diet in which 125 g of calories from fat/day or less is consumed by the individual, the method comprising administering a fat-soluble nutrient and a therapeutically effective amount of monoacylglycerols to the individual.

15. A method of improving absorption of fat-soluble nutrients in an individual having a condition in which the absorption has been compromised, the condition is selected from the group consisting of a diet low in fat, a diet low in calories, and a combination thereof, wherein the diet low in calories or the diet low in fat is a diet that solely uses liquid products restricting caloric intake while providing complete nutrition, the method comprising administering a fat-soluble nutrient and a therapeutically effective amount of monoacylglycerols to the individual.

16. The method of claim 15 wherein the monoacylglycerols are provided by one or more of the liquid products.

9000039 April 2015 Destaillats et al.
2016/0263072 September 2016 Roessle et al.
2016/0263073 September 2016 Roessle et al.
0465423 January 1992
2508180 October 2012
0119378 March 2001

Reeves, P. J. Nutr. 1997, vol. 127 pp. 8385-8415. cited by examiner
Cruz-Hernandez, C. el al., Nutrients 2012, vol. 4, pp. 1781-1793. cited by examiner
Cruz-Hernandez et al. “Benefits of Structured and Free Monoacylglycerols to Deliver Eicosapentaenoic (EPA) in a Model of Lipid Malabsorption” Nutrients, 2012, vol. 4, pp. 1781-1793. cited by applicant
Cruz-Hernandez et al. “Lipase inhibitor orlistat decreases incorporation of eicosapentaenoic and docosahexaenoic acids in rat tissues” Nutrition Research, 2010, vol. 30, pp. 134-140. cited by applicant
Article entitled “Comparison of MAG and Fish Oil Efficacy”, ClinicalTrials.gov, 2013, 4 pages. cited by applicant
Cruz-Hernandez et al. “PP077-SUN: Comparison of the Efficacy of MAG and TAG to Deliver LC-PUFA Under Malabsorption Conditions” Clinical Nutrition, 2014, vol. 33, p. S48. cited by applicant
Cruz-Hernandez, C. et al., Nutrients 2012 vol. 4, pp. 1781-1793. cited by applicant
Reeve, P. J. Nutr. 1997 vol. 127 pp. 8385-8415. cited by applicant
Nagao et al., “Effects of Fats and Oils on the Bioaccessibility of Carotenoids and Vitamin E in Vegetables”, Bioscience Biotechnology Biochemistry, 2013, vol. 77, No. 5, pp. 1055-1060. cited by applicant
Finer et al., “One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor”, International Journal of Obesity Related Metabolic Disorder, Mar. 2000, vol. 24, No. 3, pp. 306-313. cited by applicant

edspgr.10285967